Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression

Hongmin Li; Zhaofu Sheng; Suliman Khan; Ruiyi Zhang; Yang Liu; Yan Zhang; V Wee Yong; Mengzhou Xue

doi:10.3389/fneur.2022.861843

Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression

Front Neurol. 2022 Mar 18:13:861843. doi: 10.3389/fneur.2022.861843. eCollection 2022.

Authors

Hongmin Li^{1

2}, Zhaofu Sheng^{1

2}, Suliman Khan^{1

2}, Ruiyi Zhang^{1

2}, Yang Liu^{1

2}, Yan Zhang^{1

2}, V Wee Yong^{3

4}, Mengzhou Xue^{1

2}

Affiliations

¹ The Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² The Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China.
³ Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
⁴ Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Abstract

Matrix metalloproteinases (MMPs) are physiologically expressed in the central nervous system in neurons, astrocytes and microglia, and their aberrant elevation contributes to a number of diseases. Amongst the MMP members, MMP-9 has generated considerable attention because of its possible involvement in inflammatory responses, blood-brain barrier permeability, the regulation of perineuronal nets, demyelination, and synaptic long-term potentiation. Emerging evidence indicate an association between MMP-9 and the syndrome of depression. This review provides an updated and comprehensive summary of the probable roles of MMP-9 in depression with an emphasis on the mechanisms and potential of MMP-9 as a biomarker of depression.

Keywords: contributor; depression; matrix metalloproteinase 9 (MMP-9); minocycline; neuroplasticity.

Publication types

Review